{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:37:56Z","timestamp":1774935476972,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40264-022-01214-y","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:06:10Z","timestamp":1661339170000},"page":"1069-1081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prescribing Patterns of Codeine and Alternative Medicines in Children in Europe"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-4148","authenticated-orcid":false,"given":"Kelly","family":"Plueschke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Hedenmalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini-Christina","family":"Deli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Angel","family":"Maci\u00e1-Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Garc\u00eda-Poza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"1214_CR1","unstructured":"List of European Union reference dates and frequency of submission of periodic safety update reports (PSURs). https:\/\/www.ema.europa.eu\/documents\/other\/list-european-union-reference-dates-frequency-submission-periodic-safety-update-reports-psurs_en.xls. Accessed 16 June 2022."},{"key":"1214_CR2","unstructured":"Dean L, Kane M. Codeine therapy and CYP2D6 genotype. 2012 Sep 20 [updated 2021 Mar 30]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical genetics summaries [Internet]. Bethesda: National Center for Biotechnology Information (US); 2012 (PMID: 28520350)."},{"key":"1214_CR3","unstructured":"Codeine: very rare risk of side-effects in breastfed babies. Medicines and Healthcare products Regulatory Agency (MHRA) website. https:\/\/www.gov.uk\/drug-safety-update\/codeine-very-rare-risk-of-side-effects-in-breastfed-babies. Accessed 16 June 2022."},{"key":"1214_CR4","unstructured":"Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and\/or adenoidectomy. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/media\/85072\/download#:~:text=In%20August%202012%2C%20FDA%20announced,ultra%2Drapid%20metabolizers%20of%20codeine. Accessed 16 June 2022."},{"key":"1214_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0904266","author":"C Ciszkowski","year":"2009","unstructured":"Ciszkowski C, et al. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009. https:\/\/doi.org\/10.1056\/NEJMc0904266.","journal-title":"N Engl J Med"},{"issue":"5","key":"1214_CR6","doi-asserted-by":"publisher","first-page":"e1343","DOI":"10.1542\/peds.2011-2538","volume":"129","author":"LE Kelly","year":"2012","unstructured":"Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012;129(5):e1343\u20137. https:\/\/doi.org\/10.1542\/peds.2011-2538.","journal-title":"Pediatrics"},{"key":"1214_CR7","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC). https:\/\/www.ema.europa.eu\/en\/committees\/pharmacovigilance-risk-assessment-committee-prac. Accessed 16 June 2022."},{"key":"1214_CR8","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. https:\/\/eur-lex.europa.eu\/legal-content\/en\/ALL\/?uri=CELEX%3A32001L0083. Accessed 16 June 2022."},{"key":"1214_CR9","unstructured":"Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh). https:\/\/www.ema.europa.eu\/en\/committees\/working-parties-other-groups\/coordination-group-mutual-recognition-decentralised-procedures-human-cmdh. Accessed 16 June 2022."},{"key":"1214_CR10","unstructured":"Codeine-containing medicines for the treatment of pain relief in paediatric patients. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/codeine-containing-medicines. Accessed 16 June 2022."},{"key":"1214_CR11","unstructured":"Guideline on good pharmacovigilance practices (GVP) Module XV\u2014Safety communication (Rev 1). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf. Accessed 16 June 2022."},{"key":"1214_CR12","unstructured":"Codeine-containing medicinal products for the treatment of cough or cold in paediatric patients. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/codeine-containing-medicinal-products-treatment-cough-cold-paediatric-patients. Accessed 16 June 2022."},{"key":"1214_CR13","unstructured":"Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS). https:\/\/www.snds.gouv.fr\/SNDS\/Accueil. Accessed 16 June 2022."},{"issue":"10","key":"1214_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5414\/cpp47617","volume":"47","author":"H Becher","year":"2009","unstructured":"Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617\u201326. https:\/\/doi.org\/10.5414\/cpp47617.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1214_CR15","doi-asserted-by":"publisher","DOI":"10.5414\/CP203320","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, et al. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018. https:\/\/doi.org\/10.5414\/CP203320.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1214_CR16","unstructured":"Norwegian prescription database (NorPD). http:\/\/www.norpd.no\/. Accessed 16 June 2022."},{"issue":"10","key":"1214_CR17","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/pds.5006","volume":"29","author":"MA Maci\u00e1-Mart\u00ednez","year":"2020","unstructured":"Maci\u00e1-Mart\u00ednez MA, Gil M, Huerta C, et al. Base de Datos para la Investigaci\u00f3n Farmacoepidemiol\u00f3gica en Atenci\u00f3n Primaria (BIFAP): a data resource for pharmacoepidemiology in Spain. Pharmacoepidemiol Drug Saf. 2020;29(10):1236\u201345. https:\/\/doi.org\/10.1002\/pds.5006.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1214_CR18","unstructured":"IQVIA Medical Research Data (IMRD-UK) (database version used September 2018). https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/the-health-improvement-network-thin-database\/. Accessed 16 June 2022."},{"key":"1214_CR19","unstructured":"ATC\/DDD Index 2022. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 16 June 2022."},{"key":"1214_CR20","doi-asserted-by":"publisher","unstructured":"Gini, R. et al. Different strategies to execute multi-database studies for medicines surveillance in real-world setting: a reflection on the European model. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.1833","DOI":"10.1002\/cpt.1833"},{"key":"1214_CR21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x.","journal-title":"J Clin Pharm Ther"},{"key":"1214_CR22","unstructured":"Section Interrupted time series analyses of the ENCePP Guide on Methodological Standards in Pharmacoepidemiology. https:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide.shtml. Accessed 16 June 2022."},{"key":"1214_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01235-8","author":"AL Schaffer","year":"2021","unstructured":"Schaffer AL, Dobbins TA, Pearson S-A. Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. BMS Med Res Methodol. 2021. https:\/\/doi.org\/10.1186\/s12874-021-01235-8.","journal-title":"BMS Med Res Methodol."},{"key":"1214_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500208","author":"A Linden","year":"2015","unstructured":"Linden A. Conducting interrupted time-series analysis for single- and multiple-group comparisons. Sage J. 2015. https:\/\/doi.org\/10.1177\/1536867X1501500208.","journal-title":"Sage J."},{"key":"1214_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4836","author":"K Hedenmalm","year":"2019","unstructured":"Hedenmalm K, et al. A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiol Drug Saf. 2019. https:\/\/doi.org\/10.1002\/pds.4836.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1214_CR26","unstructured":"Haute Autorite de Sant\u00e9 (HAS). https:\/\/www.has-sante.fr\/jcms\/c_2010340\/en\/prise-en-charge-medicamenteuse-de-la-douleur-chez-l-enfant-alternatives-a-la-codeine. Accessed 16 June 2022."},{"key":"1214_CR27","unstructured":"HAS Fiche M\u00e9mo. Prise en charge m\u00e9dicamenteuse de la douleur chez l\u2019enfant : alternatives \u00e0 la cod\u00e9ine. Janvier 2016. https:\/\/www.sfpediatrie.com\/sites\/www.sfpediatrie.com\/files\/medias\/documents\/prise_en_charge_medicamenteuse_de_la_douleur_chez_lenfant_alternatives_a_la_codeine_-_fiche_memo.pdf. Accessed 16 June 2022."},{"key":"1214_CR28","unstructured":"Confer to the Resolution of the Spanish Ministry of Health (Resoluci\u00f3n de 2 de agosto de 2012 de la Direcci\u00f3n General de Cartera B\u00e1sica de Servicios del Sistema Nacional de Salud y Farmacia, por la que se procede a la actualizaci\u00f3n de la lista de medicamentos que quedan excluidos de la prestaci\u00f3n farmac\u00e9utica en el Sistema Nacional de Salud. https:\/\/www.boe.es\/eli\/es\/res\/2012\/08\/02\/(2). Accessed 16 June 2022."},{"key":"1214_CR29","unstructured":"UK Commission on Human Medicines. Codeine-containing liquid over-the-counter medicines. https:\/\/www.gov.uk\/drug-safety-update\/codeine-containing-liquid-over-the-counter-medicines. Accessed 16 June 2022."},{"key":"1214_CR30","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326150-00001","author":"C Bond","year":"2003","unstructured":"Bond C, Hannaford P. Issues related to monitoring the safety of over-the-counter (OTC) medicines. Drug Saf. 2003. https:\/\/doi.org\/10.2165\/00002018-200326150-00001.","journal-title":"Drug Saf."},{"key":"1214_CR31","unstructured":"Variation procedures for nationally authorised medicinal products. CMDh website. https:\/\/www.hma.eu\/human-medicines\/cmdh\/procedural-guidance\/variation.html. Accessed 16 June 2022."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01214-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T17:33:34Z","timestamp":1663781614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01214-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"11 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declared no competing interests for this work. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency\/agencies or organisations with which the author(s) is\/are employed\/affiliated. BIFAP is a public program for independent research financed by the Spanish Agency for Medicines and Medical Devices (AEMPS). The results, discussion, and conclusions of this work are only of the authors and do not represent in any way the position of the AEMPS on this subject. The excellent collaboration of the primary care physicians (general practitioners\/paediatricians) as well as the support from the regional health administrations providing BIFAP data is acknowledged.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of BIFAP data for this project was approved by the Ethics Committee (CEIM regional de la Comunidad de Madrid: aprobaci\u00f3n 08-06-2020, acta CEIm 06\/20).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The use of BIFAP data for this project was approved by the Scientific Committee of BIFAP (protocol reference: 10\/2019). The use of IMRD-UK was approved by the Scientific Review Committee under the reference number 19THIN080.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material (data transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Robert Flynn developed the study protocol, data extraction plan and table shells. All authors were consulted and agreed on these documents. Robert Flynn, Karin Hedenmalm, Aikaterini-Christina Deli, Miguel-Angel Maci\u00e1-Martinez, Patricia Garc\u00eda-Poza, David Olsen and Pierre Nguyen extracted the data from the different databases. Robert Flynn ran the analyses centrally. Kelly Plueschke, Chantal Quinten and Robert Flynn drafted the manuscript and Karin Hedenmalm, Miguel-Angel Maci\u00e1-Martinez, Patricia Garc\u00eda-Poza, David Olsen and Pierre Nguyen contributed by providing comments. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}